Premium
Neusilin® influences curcumin bioavailability and anti‐depressant efficacy in rats (1044.17)
Author(s) -
Xie Liyang,
Yohn Samantha,
Salamone John,
Bogner Robin,
Bolling Bradley
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1044.17
Subject(s) - curcumin , bioavailability , chemistry , pharmacology , depressant , medicine
Curcumin has been used to treat depression‐related disorders, but its low bioavailability may limit its efficacy. The aim of this study was to determine if Neusilin increases the acute bioavailability and anti‐depressant activity of curcumin. Fisher F344 rats were fed with either 80 or 160 mg curcumin/kg with or without co‐ground Neusilin 2 h before sacrifice. Curcumin, bisdemethoxycurcumin and demethoxycurcumin were extracted from small intestine and brain tissues and analyzed by UHPLC‐MS. Rats fed with 160 mg curcumin/kg weight with Neusilin had 51 ± 23 µg curcumin/g SI, which was at least 6‐fold higher than the other 3 treatments ( P <0.001). In the brain, curcumin content ranged from 29 to 64 ng/g brain and was not significantly different between treatments despite differences in bioactivity ( P = 0.6477). Curcumin, but not Neusilin‐formulated curcumin inhibited tetrabenazine‐induced depressive behavior (i.e., effort‐related motivational impairments) at 160 mg/kg. Thus, Neusilin formulation enhanced small intestine, but not brain curcumin bioavailability, and did not acutely improve treatment efficacy. This suggests mechanisms beyond intestinal solubility and absorption limit curcumin’s anti‐depressant efficacy. Grant Funding Source : Supported by University of Connecticut Diet and Health Initiative